Familial Cold Autoinflammatory Syndrome 4 (FCAS4) Cell Models for Research

Familial Cold Autoinflammatory Syndrome 4 (FCAS4) is an ultra-rare autoinflammatory disorder, with fewer than 1 in 1,000,000 individuals affected worldwide (WHO, 2023). It is characterized by recurrent episodes of fever, urticarial rash, and arthralgia triggered by cold exposure. The disease is caused by mutations in the NLRP12 gene, leading to dysregulated innate immune responses. Due to its rarity, epidemiological data are limited, but the condition significantly impacts quality of life, with chronic inflammation and potential long-term complications such as amyloidosis. Early diagnosis and management are crucial, but the molecular mechanisms remain incompletely understood, making it a valuable model for studying inflammasome regulation and innate immunity.

FCAS4 serves as an excellent model for investigating the molecular basis of autoinflammatory diseases. The NLRP12 gene encodes a negative regulator of NF-κB and inflammasome signaling, and its mutations provide insights into the delicate balance of immune homeostasis. Research on FCAS4 can elucidate the roles of NLRP12 in inflammatory pathways, potentially informing therapeutic strategies for other autoinflammatory conditions. Public datasets, such as those from the NCBI Gene and ClinVar, provide mutation information, while functional studies using gene-edited cell models can reveal pathogenic mechanisms. Open questions include the precise molecular consequences of specific NLRP12 mutations and their tissue-specific effects.

Although FCAS4 is not a cancer, its pathogenesis involves dysregulated inflammatory signaling pathways that are also implicated in tumorigenesis. Key pathways include:

• • NF-κB signaling: NLRP12 normally suppresses NF-κB activation; mutations lead to constitutive NF-κB activity, promoting inflammation and potentially oncogenesis.
• • Inflammasome assembly: NLRP12 can form an inflammasome complex, leading to caspase-1 activation and IL-1β/IL-18 secretion. Mutations may enhance or dysregulate this process.
• • MAPK pathway: NLRP12 also modulates MAPK signaling, and its dysregulation can affect cell proliferation and survival.

These pathways are critical in cancer development, making FCAS4 models relevant for studying inflammation-driven carcinogenesis.

Data from ClinVar and COSMIC indicate that NLRP12 mutations are the primary cause of FCAS4. The most common mutations include p.Arg284* and p.Phe402Leu, which result in truncated or altered proteins. These mutations disrupt the regulatory function of NLRP12, leading to uncontrolled inflammation.

The deregulation of NLRP12 affects multiple signaling networks:

• • NF-κB pathway: NLRP12 normally inhibits IKK complex; mutations lead to increased IκB phosphorylation and NF-κB nuclear translocation, upregulating pro-inflammatory cytokines.
• • Inflammasome signaling: NLRP12 mutations may cause spontaneous inflammasome assembly, activating caspase-1 and processing pro-IL-1β and pro-IL-18.
• • MAPK/ERK pathway: NLRP12 interacts with TRAF3 and TAK1, modulating MAPK activation. Mutations can lead to sustained ERK signaling, promoting cell proliferation.
• • Interferon signaling: NLRP12 also regulates type I interferon responses; its loss may impair antiviral immunity.

These networks are interconnected, and their dysregulation contributes to the systemic inflammation seen in FCAS4.

Organoid models derived from patient-derived induced pluripotent stem cells (iPSCs) can recapitulate tissue-specific inflammation. These 3D cultures allow for studying cell-cell interactions and drug responses in a more physiologically relevant context.

• • Genetically engineered mouse models (GEMMs): Mice with Nlrp12 knockout or knock-in mutations have been developed to study FCAS4. These mice exhibit enhanced inflammation upon cold exposure, mimicking the human phenotype.
• • Patient-derived xenografts (PDX): Not commonly used for FCAS4 due to its non-cancerous nature, but immune cell transfer models can be employed.
• • Induced models: Chemical or genetic induction of NLRP12 mutations in mice via CRISPR can create conditional models for tissue-specific studies.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific NLRP12 mutations. For example, a NLRP12 knockout THP-1 cell line can be generated to study loss-of-function effects, while a knock-in line with a common mutation like p.Arg284* can model the disease. These sequence-verified models are commercially available and accelerate research by providing consistent, reproducible systems. They are essential for functional studies, drug screening, and understanding the molecular basis of FCAS4.

Gene-edited cell lines are invaluable for functional genomics. For instance, NLRP12 knockout THP-1 cells can be used to identify downstream targets of NLRP12 via transcriptomic analysis. Knock-in lines with specific mutations allow for genotype-phenotype correlations. These models help validate the role of NLRP12 in NF-κB and inflammasome signaling, and can be used in CRISPR screens to identify modifiers of the inflammatory response.

Isogenic cell line pairs (wild-type vs. NLRP12 mutant) are powerful tools for drug screening. They can be used to test anti-inflammatory compounds that target NF-κB or inflammasome pathways. Additionally, these models can be used to study drug resistance mechanisms, as chronic inflammation may lead to adaptive changes. High-throughput screening with these cells can identify novel therapeutic agents for FCAS4 and related autoinflammatory diseases.

CRISPR synthetic lethality screens using NLRP12-deficient cells can identify genes that are essential for cell survival in the context of NLRP12 loss. This approach can reveal novel therapeutic targets and biomarkers. For example, if a specific kinase is synthetically lethal with NLRP12 knockout, it could serve as a drug target. Additionally, secretome analysis of mutant cells can identify inflammatory cytokines that serve as biomarkers for disease activity.